Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials

• Main Author: Ibrahim Ezzeldin
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2010-01-01
• Series: Annals of Thoracic Medicine
• Subjects: EGFR; gefitinib; non-small cell lung cancer
• Online Access: http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2010;volume=5;issue=3;spage=153;epage=160;aulast=Ibrahim

<b>Objective</b> : Gefitinib, a small molecule tyrosine kinase inhibitor, showed a substantial effect as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) who had failed prior chemotherapy. Subsequent phase III trials in previously untreated patients have failed to demonstrate such benefit. It was later reported that gefitinib had a positive outcome when used in selected population.<b> Rational</b> : The inconsistent results and the lack published meta-analysis that systematically examined the overall efficacy of gefitinib in the frontline setting in such patients, have prompted the current meta-analysis. <b> Methods</b> : We selected for analysis only those randomized, peer-reviewed clinical studies where the efficacy of gefitinib-based therapy (GBT) was investigated in chemotherapy na&#959;ve patients with locally advanced or metastatic NSCLC. We also included studies where patients were randomized between gefitinib vs. placebo or none after initial chemoradiation or chemotherapy induction offered to all included patients. <b> Results</b> : We identified seven eligible studies involving 2,646 and 1,939 patients randomized to GBT and to control arms, respectively. In mostly unselected population, GBT was not associated with higher objective response rate (ORR), progression-free survival (PFS) (hazard ratio [HR] = 0.97, 95&#x0025; CI: 0.78-1.20, <i>P</i> = 0.78), or overall survival (OS) (HR = 1.04, 95&#x0025; CI: 0.95-1.13, <i>P</i> = 0.45) as compared with control interventions. In a fraction of patients with known EGFR mutation status, GBT showed significantly higher ORR among patients with mutant EGFR (odds ratio [OR] = 2.81, 95&#x0025; CI: 1.71-4.62, <i>P</i> &lt; 0.0001); however, EGFR mutation was not associated with better PFS or OS with GBT. Nevertheless, patients receiving GBT experienced significant improvement in quality of life as compared with those in the control arms. <b>Conclusion</b> : We conclude that GBT cannot be recommended for frontline management of patients with advanced NSCLC in unselected patient population.